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A PRE-ENDOSCOPY POINT OF CARE TEST (IGA/IGG- DEAMIDATED GLIADIN 
PEPTIDE) AS A CASE FINDING TOOL FOR COELIAC DISEASEIN SECONDARY 
CARE  
MS Lau*, PD Mooney, WL White, MA Rees, M Burden, SH Wong, M Kurien, DS 
Sanders.  
Academic Unit of Gastroenterology, Royal Hallamshire Hospital, Sheffield, UK  
 
Introduction Coeliac disease (CD) is common yet underdiagnosed. 12.4% CD 
patients had a gastroscopy within 5 years without duodenal biopsies taken, and 
coeliac serology was performed in only 30% of patients with anaemia or suspected 
CD. A pre-endoscopy point of care test (POCT) could potentially fill this gap. We 
aimed to evaluate the diagnostic accuracy and acceptability of the POCT, Simtomax 
(IgA/IgG-deamidated gliadin peptide, Tillotts Pharma, Rheinfelden, Switzerland), in 
detecting CD. 
 
Method Group 1: Patients attending for a gastroscopy were prospectively recruited 
from 2013±17. We excluded patients with a high pre-test probability of CD: positive 
endomysial antibody (EMA) referrals, previous villous atrophy, self-reported gluten 
sensitivity, those on a gluten free diet (GFD), suspected gluten ataxia; and known 
CD. Group 2: Patients who self-reported gluten sensitivity were prospectively 
recruited. All patients underwent the POCT, tissue transglutaminase antibodies 
(TTG), EMA and duodenal biopsies. The sensitivities of the POCT were compared to 
TTG and EMA, measuring against histology as the reference standard. 
Questionnaires regarding patient preference to the modality of antibody testing were 
given out. 
 
Results Group 1: 1000 patients were recruited (585 females, 58.5%; age 
range 16±91, median age 57). Forty-one patients (4.1%) were diagnosed with 
CD. Group 2: Seventy patients who self-reported gluten sensitivity were 
recruited (51 females, 82.9%; age range 17±73, median age 35). Nine 
patients on a self-imposed GFD were excluded. Of the remaining 61 patients, 
42 (68.9%) were diagnosed with non-coeliac gluten sensitivity (NCGS), 17 
(27.9%) with CD and 2 (3.3%) with potential CD. Five hundred patients 
responded to the POCT acceptability questionnaire. 90.8% preferred a POCT, 
2.8% preferred venepuncture, and 6.8% had no preference. 
 
Conclusion The POCT had comparable diagnostic performance to 
conventional serology. It also correctly identified all cases of CD in a gluten 
sensitive cohort. The POCT could serve as a valuable and convenient case 
finding tool, with the advantage of providing antibody results rapidly at the 
point of endoscopy to target duodenal biopsy sampling for those with a 
positive POCT. 
 
 
 
